Report cover image

Global Cancer Immunotherapies Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 190 Pages
SKU # APRC20561498

Description

Summary

According to APO Research, The global Cancer Immunotherapies market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Cancer Immunotherapies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Cancer Immunotherapies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Cancer Immunotherapies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Cancer Immunotherapies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Cancer Immunotherapies include ARMO BioSciences (Eli Lilly), Bristol-Myers Squibb, Gilead Sciences, AstraZeneca, AbbVie, Amgen, Bayer, Pfizer and Roche, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Cancer Immunotherapies, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Cancer Immunotherapies, also provides the sales of main regions and countries. Of the upcoming market potential for Cancer Immunotherapies, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cancer Immunotherapies sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Cancer Immunotherapies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Cancer Immunotherapies sales, projected growth trends, production technology, application and end-user industry.

Cancer Immunotherapies Segment by Company

ARMO BioSciences (Eli Lilly)
Bristol-Myers Squibb
Gilead Sciences
AstraZeneca
AbbVie
Amgen
Bayer
Pfizer
Roche
Merck
Novartis
Johnson & Johnson
Cancer Immunotherapies Segment by Type

Immunomodulators
Checkpoint Inhibitors
Adoptive Cell transfer
Monoclonal Antibodies (MABs)
Cancer Vaccines
Cancer Immunotherapies Segment by Application

Breast Cancer
Lymphoma
Colorectal Cancer
Melanoma
Non-Small Cell Lung Cancer
Leukemia
Cancer Immunotherapies Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Immunotherapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cancer Immunotherapies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Immunotherapies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Cancer Immunotherapies in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Cancer Immunotherapies manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Immunotherapies sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

190 Pages
1 Market Overview
1.1 Product Definition
1.2 Cancer Immunotherapies Market by Type
1.2.1 Global Cancer Immunotherapies Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Immunomodulators
1.2.3 Checkpoint Inhibitors
1.2.4 Adoptive Cell transfer
1.2.5 Monoclonal Antibodies (MABs)
1.2.6 Cancer Vaccines
1.3 Cancer Immunotherapies Market by Application
1.3.1 Global Cancer Immunotherapies Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Breast Cancer
1.3.3 Lymphoma
1.3.4 Colorectal Cancer
1.3.5 Melanoma
1.3.6 Non-Small Cell Lung Cancer
1.3.7 Leukemia
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Cancer Immunotherapies Market Dynamics
2.1 Cancer Immunotherapies Industry Trends
2.2 Cancer Immunotherapies Industry Drivers
2.3 Cancer Immunotherapies Industry Opportunities and Challenges
2.4 Cancer Immunotherapies Industry Restraints
3 Global Market Growth Prospects
3.1 Global Cancer Immunotherapies Revenue Estimates and Forecasts (2020-2031)
3.2 Global Cancer Immunotherapies Revenue by Region
3.2.1 Global Cancer Immunotherapies Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Cancer Immunotherapies Revenue by Region (2020-2025)
3.2.3 Global Cancer Immunotherapies Revenue by Region (2026-2031)
3.2.4 Global Cancer Immunotherapies Revenue Market Share by Region (2020-2031)
3.3 Global Cancer Immunotherapies Sales Estimates and Forecasts 2020-2031
3.4 Global Cancer Immunotherapies Sales by Region
3.4.1 Global Cancer Immunotherapies Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Cancer Immunotherapies Sales by Region (2020-2025)
3.4.3 Global Cancer Immunotherapies Sales by Region (2026-2031)
3.4.4 Global Cancer Immunotherapies Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Cancer Immunotherapies Revenue by Manufacturers
4.1.1 Global Cancer Immunotherapies Revenue by Manufacturers (2020-2025)
4.1.2 Global Cancer Immunotherapies Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Cancer Immunotherapies Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Cancer Immunotherapies Sales by Manufacturers
4.2.1 Global Cancer Immunotherapies Sales by Manufacturers (2020-2025)
4.2.2 Global Cancer Immunotherapies Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Cancer Immunotherapies Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Cancer Immunotherapies Sales Price by Manufacturers (2020-2025)
4.4 Global Cancer Immunotherapies Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Cancer Immunotherapies Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Cancer Immunotherapies Manufacturers, Product Type & Application
4.7 Global Cancer Immunotherapies Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Cancer Immunotherapies Market CR5 and HHI
4.8.2 2024 Cancer Immunotherapies Tier 1, Tier 2, and Tier 3
5 Cancer Immunotherapies Market by Type
5.1 Global Cancer Immunotherapies Revenue by Type
5.1.1 Global Cancer Immunotherapies Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Cancer Immunotherapies Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Cancer Immunotherapies Revenue Market Share by Type (2020-2031)
5.2 Global Cancer Immunotherapies Sales by Type
5.2.1 Global Cancer Immunotherapies Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Cancer Immunotherapies Sales by Type (2020-2031) & (k units)
5.2.3 Global Cancer Immunotherapies Sales Market Share by Type (2020-2031)
5.3 Global Cancer Immunotherapies Price by Type
6 Cancer Immunotherapies Market by Application
6.1 Global Cancer Immunotherapies Revenue by Application
6.1.1 Global Cancer Immunotherapies Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Cancer Immunotherapies Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Cancer Immunotherapies Revenue Market Share by Application (2020-2031)
6.2 Global Cancer Immunotherapies Sales by Application
6.2.1 Global Cancer Immunotherapies Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Cancer Immunotherapies Sales by Application (2020-2031) & (k units)
6.2.3 Global Cancer Immunotherapies Sales Market Share by Application (2020-2031)
6.3 Global Cancer Immunotherapies Price by Application
7 Company Profiles
7.1 ARMO BioSciences (Eli Lilly)
7.1.1 ARMO BioSciences (Eli Lilly) Comapny Information
7.1.2 ARMO BioSciences (Eli Lilly) Business Overview
7.1.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Portfolio
7.1.5 ARMO BioSciences (Eli Lilly) Recent Developments
7.2 Bristol-Myers Squibb
7.2.1 Bristol-Myers Squibb Comapny Information
7.2.2 Bristol-Myers Squibb Business Overview
7.2.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Bristol-Myers Squibb Cancer Immunotherapies Product Portfolio
7.2.5 Bristol-Myers Squibb Recent Developments
7.3 Gilead Sciences
7.3.1 Gilead Sciences Comapny Information
7.3.2 Gilead Sciences Business Overview
7.3.3 Gilead Sciences Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Gilead Sciences Cancer Immunotherapies Product Portfolio
7.3.5 Gilead Sciences Recent Developments
7.4 AstraZeneca
7.4.1 AstraZeneca Comapny Information
7.4.2 AstraZeneca Business Overview
7.4.3 AstraZeneca Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 AstraZeneca Cancer Immunotherapies Product Portfolio
7.4.5 AstraZeneca Recent Developments
7.5 AbbVie
7.5.1 AbbVie Comapny Information
7.5.2 AbbVie Business Overview
7.5.3 AbbVie Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 AbbVie Cancer Immunotherapies Product Portfolio
7.5.5 AbbVie Recent Developments
7.6 Amgen
7.6.1 Amgen Comapny Information
7.6.2 Amgen Business Overview
7.6.3 Amgen Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Amgen Cancer Immunotherapies Product Portfolio
7.6.5 Amgen Recent Developments
7.7 Bayer
7.7.1 Bayer Comapny Information
7.7.2 Bayer Business Overview
7.7.3 Bayer Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Bayer Cancer Immunotherapies Product Portfolio
7.7.5 Bayer Recent Developments
7.8 Pfizer
7.8.1 Pfizer Comapny Information
7.8.2 Pfizer Business Overview
7.8.3 Pfizer Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Pfizer Cancer Immunotherapies Product Portfolio
7.8.5 Pfizer Recent Developments
7.9 Roche
7.9.1 Roche Comapny Information
7.9.2 Roche Business Overview
7.9.3 Roche Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Roche Cancer Immunotherapies Product Portfolio
7.9.5 Roche Recent Developments
7.10 Merck
7.10.1 Merck Comapny Information
7.10.2 Merck Business Overview
7.10.3 Merck Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Merck Cancer Immunotherapies Product Portfolio
7.10.5 Merck Recent Developments
7.11 Novartis
7.11.1 Novartis Comapny Information
7.11.2 Novartis Business Overview
7.11.3 Novartis Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 Novartis Cancer Immunotherapies Product Portfolio
7.11.5 Novartis Recent Developments
7.12 Johnson & Johnson
7.12.1 Johnson & Johnson Comapny Information
7.12.2 Johnson & Johnson Business Overview
7.12.3 Johnson & Johnson Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
7.12.4 Johnson & Johnson Cancer Immunotherapies Product Portfolio
7.12.5 Johnson & Johnson Recent Developments
8 North America
8.1 North America Cancer Immunotherapies Market Size by Type
8.1.1 North America Cancer Immunotherapies Revenue by Type (2020-2031)
8.1.2 North America Cancer Immunotherapies Sales by Type (2020-2031)
8.1.3 North America Cancer Immunotherapies Price by Type (2020-2031)
8.2 North America Cancer Immunotherapies Market Size by Application
8.2.1 North America Cancer Immunotherapies Revenue by Application (2020-2031)
8.2.2 North America Cancer Immunotherapies Sales by Application (2020-2031)
8.2.3 North America Cancer Immunotherapies Price by Application (2020-2031)
8.3 North America Cancer Immunotherapies Market Size by Country
8.3.1 North America Cancer Immunotherapies Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Cancer Immunotherapies Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Cancer Immunotherapies Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
8.3.6 Mexico
9 Europe
9.1 Europe Cancer Immunotherapies Market Size by Type
9.1.1 Europe Cancer Immunotherapies Revenue by Type (2020-2031)
9.1.2 Europe Cancer Immunotherapies Sales by Type (2020-2031)
9.1.3 Europe Cancer Immunotherapies Price by Type (2020-2031)
9.2 Europe Cancer Immunotherapies Market Size by Application
9.2.1 Europe Cancer Immunotherapies Revenue by Application (2020-2031)
9.2.2 Europe Cancer Immunotherapies Sales by Application (2020-2031)
9.2.3 Europe Cancer Immunotherapies Price by Application (2020-2031)
9.3 Europe Cancer Immunotherapies Market Size by Country
9.3.1 Europe Cancer Immunotherapies Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Cancer Immunotherapies Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Cancer Immunotherapies Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
9.3.9 Spain
9.3.10 Netherlands
10 China
10.1 China Cancer Immunotherapies Market Size by Type
10.1.1 China Cancer Immunotherapies Revenue by Type (2020-2031)
10.1.2 China Cancer Immunotherapies Sales by Type (2020-2031)
10.1.3 China Cancer Immunotherapies Price by Type (2020-2031)
10.2 China Cancer Immunotherapies Market Size by Application
10.2.1 China Cancer Immunotherapies Revenue by Application (2020-2031)
10.2.2 China Cancer Immunotherapies Sales by Application (2020-2031)
10.2.3 China Cancer Immunotherapies Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Cancer Immunotherapies Market Size by Type
11.1.1 Asia Cancer Immunotherapies Revenue by Type (2020-2031)
11.1.2 Asia Cancer Immunotherapies Sales by Type (2020-2031)
11.1.3 Asia Cancer Immunotherapies Price by Type (2020-2031)
11.2 Asia Cancer Immunotherapies Market Size by Application
11.2.1 Asia Cancer Immunotherapies Revenue by Application (2020-2031)
11.2.2 Asia Cancer Immunotherapies Sales by Application (2020-2031)
11.2.3 Asia Cancer Immunotherapies Price by Application (2020-2031)
11.3 Asia Cancer Immunotherapies Market Size by Country
11.3.1 Asia Cancer Immunotherapies Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Cancer Immunotherapies Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Cancer Immunotherapies Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Cancer Immunotherapies Market Size by Type
12.1.1 SAMEA Cancer Immunotherapies Revenue by Type (2020-2031)
12.1.2 SAMEA Cancer Immunotherapies Sales by Type (2020-2031)
12.1.3 SAMEA Cancer Immunotherapies Price by Type (2020-2031)
12.2 SAMEA Cancer Immunotherapies Market Size by Application
12.2.1 SAMEA Cancer Immunotherapies Revenue by Application (2020-2031)
12.2.2 SAMEA Cancer Immunotherapies Sales by Application (2020-2031)
12.2.3 SAMEA Cancer Immunotherapies Price by Application (2020-2031)
12.3 SAMEA Cancer Immunotherapies Market Size by Country
12.3.1 SAMEA Cancer Immunotherapies Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Cancer Immunotherapies Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Cancer Immunotherapies Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Cancer Immunotherapies Value Chain Analysis
13.1.1 Cancer Immunotherapies Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Cancer Immunotherapies Production Mode & Process
13.2 Cancer Immunotherapies Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Cancer Immunotherapies Distributors
13.2.3 Cancer Immunotherapies Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.